MedPath

GRUPO COOPERATIVO DE ESTUDIO Y TRATAMIENTO DE LAS LEUCEMIAS AGUDAS Y MIELODISPLASIAS

🇪🇸Spain
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

8

Active:1
Completed:5

Trial Phases

2 Phases

Phase 1:1
Phase 2:6

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 2
6 (85.7%)
Phase 1
1 (14.3%)

Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

Phase 2
Recruiting
Conditions
Acute Myeloid Leukemia
Interventions
First Posted Date
2024-10-31
Last Posted Date
2025-05-15
Lead Sponsor
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Target Recruit Count
29
Registration Number
NCT06668558
Locations
🇪🇸

University Hospital Son Espases, Palma de Mallorca, Baleares, Spain

🇪🇸

Hospital Son Llatzer, Palma de Mallorca, Baleares, Spain

🇪🇸

Institut Catala D oncologia Badalona, Badalona, Cataluña, Spain

and more 11 locations

Risk-adapted Therapy for Primary Acute Myeloid Leukemia

Phase 2
Completed
Conditions
Leukemia, Myeloid, Acute
Interventions
Procedure: Allogeneic matched or unrelated donor transplant.
Procedure: Autologous peripheral blood stem cell transplant
Procedure: Measurable residual disease
First Posted Date
2020-12-29
Last Posted Date
2023-06-27
Lead Sponsor
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Target Recruit Count
1034
Registration Number
NCT04687098
Locations
🇪🇸

ICO Badalona-Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain

🇪🇸

ICO Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain

🇪🇸

Hospital Universitari Son Espases, Palma de Mallorca, Mallorca, Spain

and more 12 locations

Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)

Conditions
Myelodysplastic Syndromes
Interventions
First Posted Date
2020-10-26
Last Posted Date
2020-10-26
Lead Sponsor
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Target Recruit Count
150
Registration Number
NCT04602273
Locations
🇪🇸

Son Llàtzer, Palma, Islas Baleares, Spain

Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)

Phase 2
Completed
Conditions
Leukemia, Myelocytic, Acute
Interventions
Other: Autologous peripheral blood stem cell transplantation.
Other: Allogeneic matched related or unrelated donor transplant.
Other: CD34+ selection.
Other: Mylotarg purging before autologous PBSC transplantation
First Posted Date
2012-11-08
Last Posted Date
2012-11-08
Lead Sponsor
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Target Recruit Count
862
Registration Number
NCT01723657
Locations
🇪🇸

Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain

🇪🇸

ICO Hospital Universitari de Bellvitge, L'Hospitalet del Llobregat, Barcelona, Spain

🇪🇸

Hospital A Coruña, A Coruña, Coruña, Spain

and more 18 locations

Risk-adapted Therapy for Adult Acute Myeloid Leukemia.

Phase 2
Completed
Conditions
Leukemia, Myelocytic, Acute
Interventions
Other: Autologous transplantation
Other: Allogeneic HLA-identical sibling transplantation
Other: CD34+ selection
First Posted Date
2012-10-30
Last Posted Date
2012-11-01
Lead Sponsor
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Target Recruit Count
354
Registration Number
NCT01716793
Locations
🇪🇸

Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

🇪🇸

ICO Hospital Universitari de Bellvitge, L'Hospitalet del Llobregat, Barcelona, Spain

🇪🇸

Hospital A Coruña, A Coruña, Coruña, Spain

and more 16 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.